Haseeb Ahmed | BiotechTV

top of page

From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication

From Syncona's Capital Markets Day, CEO Haseeb Ahmed describes the science behind the platform, and make the case why IgAN, a condition that has seen a bevy of new therapies in development, is the right indication for a gene therapy.

Company News

8 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication

Follow BiotechTV

Sponsors

Sponsor Spotlight